News OptiNose, Inc.

Equities

OPTN

US68404V1008

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
1.19 ^USD	-2.46%		-10.53%	-7.75%

Mar. 18	Lake Street Adjusts Price Target on OptiNose to $4 From $3, Maintains Buy Rating	MT
Mar. 18	Sector Update: Health Care Stocks Steady Premarket Monday	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Optinose to Present at the Needham Virtual Healthcare Conference	Apr. 04	AQ
Lake Street Adjusts Price Target on OptiNose to $4 From $3, Maintains Buy Rating	Mar. 18	MT
Sector Update: Health Care Stocks Steady Premarket Monday	Mar. 18	MT
OptiNose Says US FDA Approves Xhance to Treat Chronic Rhinosinusitis	Mar. 15	MT
Optinose Says FDA Approves Xhance to Treat Chronic Rhinosinusitis	Mar. 15	DJ
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps	Mar. 15	AQ
OptiNose, Inc. Announces U.S. Food and Drug Administration Approved XHANCE (Fluticasone Propionate) Nasal Spray for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps in Patients 18 Years of Age and Older	Mar. 15	CI
Optinose, Inc. Provides Update on Hikma Manufacturing Agreement	Mar. 14	CI
Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?	Mar. 14	PR
HC Wainwright Initiates OptiNose With Buy Rating, $5 Price Target	Mar. 11	MT
Transcript : OptiNose, Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
OptiNose: Q4 Earnings Snapshot	Mar. 07	AQ
Earnings Flash (OPTN) OPTINOSE Posts Q4 Revenue $19.9M	Mar. 07	MT
OptiNose, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights	Mar. 07	AQ
OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024	Mar. 07	CI
OptiNose, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
North American Morning Briefing : Powell Still in -2-	Mar. 07	DJ
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results	Feb. 29	AQ
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice	Jan. 18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News OptiNose, Inc.

Equities

OPTN

US68404V1008

Summary

Filters